​​​
​
Mini-CARTM represent a groundbreaking advancement in targeted drug therapy. Derived from allogenic cells, these genetically null miniaturized cells are engineered from induced pluripotent stem cells (iPSCs) that possess remarkable properties. By imbuing iPSCs with allogenic, anti-phagocytic, check point inhibition, and anti-cytotoxic properties, we've created a versatile platform for integrating targeting moieties, such as Chimeric Antigen Receptor (CAR) constructs.
​
The process begins with the integration of CAR constructs into the iPSC line, which is then differentiated into the desired lineage. This optimized lineage ensures superior Mini-CAR tissue penetration and cellular targeting. Through our proprietary protocols, these cells undergo activated apoptotic protein expression then processed using a specialized serial extrusion method, enabling the mass production of Mini-CARs.
​
What sets the Mini-CAR apart is its unique composition. With a high concentration of lipid variants and high surface density of critical proteins, it offers unparalleled potency in targeting, cellular adhesion, and cellular uptake. This advancement represents a significant leap forward in the field of CAR therapy, promising more effective and precise treatments for a wide range of diseases.
Mini-CAR BioSpheres: Revolutionizing Targeted Drug Therapy
Immunological
Synapse
Lytic
Granules
Lymphocyte
Cancer Cell
​
​
The Mini-CAR represents a significant advancement in targeted drug therapy, with its key differentiator being the CAR construct. Unlike other targeting approaches, such as antibodies or ligands, the CAR construct offers a dual advantage. First, it leverages the activating features of its intracellular domains to induce the cellular expression of a desired gene, enabling the production of therapeutic proteins or RNA - an achievement unattainable with a simple targeting ligand lacking a signaling domain. Second, the CAR construct's ability to form an immunological synapse (IS) is pivotal. This feature allows us to meticulously select CAR constructs with optimal binding and cellular uptake properties, ensuring precise targeting of the diseased cell while significantly reducing off-target effects. These effects, which may lead to adverse events like cytokine release syndrome (CRS) and inflammation, are mitigated through the CAR construct's specific binding mechanism. Additionally, we use cutting-edge Artificial Intelligence programming that enables rapid assessment of the CAR construct's quality on its intended cellular target within the designated patient population, ensuring the safest and most efficacious outcomes. This comprehensive approach underscores our commitment to advancing the field of CAR therapies for the benefit of patients worldwide.
Catalyzing Precision Medicine: The Power of AI Designed CAR Constructs in Mini-CAR BioSpheres
​
Many biologic therapeutic technologies face significant challenges in scalability and manufacturing, limiting their potential impact. Issues such as poor yield, lack of homogeneity, high cost, limited drug loading, and batch inconsistency plague many existing methods. Mini-CAR, however, represent a paradigm shift in overcoming these hurdles. With a clear pathway to GMP manufacturing for commercialization, Mini-CARs offer a scalable solution with unmatched efficiency.
​
Mini-CARs can be produced in very large quantities, thereby considerably offsetting costs associated with upstream cellular growth and expansion systems. Furthermore, Mini-CARs have negligible cytotoxic effects due to their allogenic nature.​
Scaling New Heights: Mini-CAR BioSpheres Pioneer Next-Gen CAR-Drug Manufacturing
